Related Experiment Video

Updated: Aug 16, 2025

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.6K

Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis

Jordyn A Lopes1, Amira D Rghei1, Brad Thompson2

  • 1Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Biomedicines
|December 23, 2022
PubMed

Insights

Pseudomonas aeruginosa infections are a growing problem due to antibiotic resistance. Vectored immunoprophylaxis (VIP) using adeno-associated virus (AAV) vectors offers a promising new strategy to combat these infections.

Area of Science:

  • Bacteriology
  • Immunology
  • Gene Therapy

Background:

  • Pseudomonas aeruginosa is a significant nosocomial pathogen, causing severe infections, particularly in immunocompromised individuals and cystic fibrosis patients.
  • Rising multidrug resistance in P. aeruginosa necessitates alternative therapeutic strategies beyond antibiotics.
  • Currently, no licensed vaccines exist for P. aeruginosa infections.

Purpose of the Study:

  • To review the biology and pathogenesis of Pseudomonas aeruginosa.
  • To discuss current and emerging treatment strategies for P. aeruginosa infections.
  • To highlight adeno-associated virus-vectored immunoprophylaxis (AAV-VIP) as a novel therapeutic platform.

Main Methods:

  • Review of existing literature on P. aeruginosa biology, pathogenesis, and treatment.
  • Analysis of current therapeutic approaches, including antibiotics.
  • Exploration of novel strategies, focusing on AAV-VIP.

Main Results:

  • P. aeruginosa exhibits complex resistance mechanisms, complicating antibiotic treatment.
  • AAV-VIP demonstrates potential for sustained in vivo production of monoclonal antibodies.
  • AAV-VIP offers a promising alternative for prophylaxis and treatment.

Conclusions:

  • The increasing prevalence of multidrug-resistant P. aeruginosa demands innovative solutions.
  • AAV-VIP represents a novel and promising therapeutic platform for P. aeruginosa infections.
  • Further research into AAV-VIP could lead to effective vaccines or treatments.
Keywords:
Pseudomonas aeruginosaadeno-associated virus (AAV)chronic infectionscystic fibrosismonoclonal antibodiesnosocomial infectionsvectored immunoprophylaxis (VIP)

More Related Videos

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

3.5K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

11.0K

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.3K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.3K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
417
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.7K